A phase II trial of afatinib (BIBW 2992) in patients (pts) with advanced non-small cell lung cancer previously treated with erlotinib (E) or gefitinib (G).
Nobuyuki Yamamoto(Wakayama Medical University), Maryam Shahidi(Royal Marsden NHS Foundation Trust), Keigo Kobayashi(Osaka Gakuin University), Yoko Seki, Naoyuki Nogami(Hospital Universitario Insular de Gran Canaria), Keiko Goto(Juntendo University), A. Inoue, Shinji Atagi(National Institute of Technology, Nara College), Katsuyuki Kiura(Okayama University Hospital), Tomoyuki Hida(Brigham and Women's Hospital), Robert M. Lorence, Hideo Saka(Nagoya Medical Center), Nobuyuki Katakami(Takarazuka City Hospital), Tomohide Tamura(St. Luke's International Hospital), Isamu Okamoto(Kyushu University), K. Takeda, Takeshi Horai, Ryotaro Morinaga, Y. Ichinose, Kazuto Nishio(Kindai University Sakai Hospital)
Cited by 25
Related Papers
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials
|The Lancet Oncology|2015|1.6k
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
|The Lancet Oncology|2015|980
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial
|The Lancet Respiratory Medicine|2019|937
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
|Science Translational Medicine|2011|670